Payment overview · 2025
General Payments
$273.28
16 reported records · 13 companies
Healthcare provider profile · identity verified
James J Bomer, MD
Allopathic & Osteopathic Physicians|Family Medicine · SYLVANIA, OH · NPI 1033470018
Verified facts
What the public records show
CMS Open Payments records show James J Bomer, MD received $273.28 in general payments during 2025 across 16 reported records.
Amgen Inc. accounted for 12.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.51 | 12.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.43 | 12.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.33 | 10.7% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $22.00 | 8.1% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $20.63 | 7.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.42 | 7.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.16 | 7.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.21 | 6.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.35 | 6.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.86 | 5.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.50 | 5.3% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $14.33 | 5.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.55 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $273.28 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.33 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 71 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 581 | 183 |
| Levothyroxine Sodium | Levothyroxine Sodium | 395 | 127 |
| Lisinopril | Lisinopril | 393 | 125 |
| Hydrochlorothiazide | Hydrochlorothiazide | 324 | 108 |
| Losartan Potassium | Losartan Potassium | 320 | 98 |
| Sertraline Hcl | Sertraline Hcl | 314 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 310 | 93 |
| Metformin Hcl | Metformin Hcl | 208 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 204 | 61 |
| Omeprazole | Omeprazole | 172 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 156 | 51 |
| Simvastatin | Simvastatin | 155 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 39 |
| Allopurinol | Allopurinol | 117 | 35 |
| Donepezil Hcl | Donepezil Hcl | 117 | 21 |
| Meloxicam | Meloxicam | 111 | 35 |
| Alprazolam | Alprazolam | 109 | 44 |
| Metformin Hcl Er | Metformin Hcl | 108 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 25 |
| Atenolol | Atenolol | 103 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | 24 |
| Prednisone | Prednisone | 92 | 74 |
| Furosemide | Furosemide | 91 | 26 |
| Glipizide | Glipizide | 87 | 27 |
| Gabapentin | Gabapentin | 81 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 79 | 22 |
| Trazodone Hcl | Trazodone Hcl | 75 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 18 |
| Eliquis | Apixaban | 71 | 15 |
| Lorazepam | Lorazepam | 66 | 27 |
| Carvedilol | Carvedilol | 65 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 19 |
| Tramadol Hcl | Tramadol Hcl | 62 | 17 |
| Azelastine Hcl | Azelastine Hcl | 59 | 30 |
| Azithromycin | Azithromycin | 59 | 49 |
| Celecoxib | Celecoxib | 58 | 16 |
| Buspirone Hcl | Buspirone Hcl | 55 | 14 |
| Potassium Chloride | Potassium Chloride | 54 | 19 |
| Januvia | Sitagliptin Phosphate | 52 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | suppressed |
| Ozempic | Semaglutide | 49 | suppressed |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Spironolactone | Spironolactone | 46 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | suppressed |
| Nifedipine Er | Nifedipine | 43 | 11 |
| Bupropion Xl | Bupropion Hcl | 42 | 11 |
| Synthroid | Levothyroxine Sodium | 41 | 14 |
| Meclizine Hcl | Meclizine Hcl | 40 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 13 |
| Famotidine | Famotidine | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | 12 |
| Terazosin Hcl | Terazosin Hcl | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 24 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 11 |
| Naproxen | Naproxen | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 14 |
| Finasteride | Finasteride | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 19 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Piroxicam | Piroxicam | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Klor-Con M10 | Potassium Chloride | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $273.28 · 16 records | Amgen Inc. | AREXVY, BEXSERO, Cologuard Collection Kit, ELIQUIS, INSPIRE, JOURNAVX, MOUNJARO, NEFFY, NURTEC ODT, REPATHA, SHINGRIX, Senza, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error